First human test for new Alzheimer's drug begins
NCT ID NCT05551741
Summary
This was the first study in people to test the safety and side effects of a new drug called IBC-Ab002 for early Alzheimer's disease. The study involved 40 participants who received either the drug or a placebo through an IV. The main goal was to see how safe the drug was and how it moved through the body, not to measure how well it worked against Alzheimer's symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barzilai Medical Center
Ashkelon, Israel
-
Brain Research Center
Amsterdam, Netherlands
-
Dementia Research Centre, National Hospital for Neurology and Neurosurgery
London, United Kingdom
-
King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN)
London, SE5 8AF, United Kingdom
-
RICE - Research Institute for the Care of Older People
Bath, BA1 3NG, United Kingdom
-
Rabin Medical Center
Petah Tikva, Israel
-
Sheba Medical Center
Ramat Gan, Israel
-
Sheffield teaching Hospitals NHS Trust
London, United Kingdom
-
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
-
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, United Kingdom
Conditions
Explore the condition pages connected to this study.